Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.59 |
| ▸ | MMP1 | P03956 | 3/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.59 |
| ▸ | MMP9 | P14780 | 3/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302448 | 0.83 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL6302452 | 0.83 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL9840923 | 0.83 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL14154228 | 0.82 | MMP1 (0.66) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL1772810 | 0.82 | MMP1 (0.66) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL725250 | 0.81 | TGM2 (0.65) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL2664164 | 0.79 | TGM2 (0.63) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL5830369 | 0.79 | TGM2 (0.63) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL9080645 | 0.79 | TGM2 (0.63) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL6581501 | 0.79 | TGM2 (0.63) | TGM2CYP1A2NPSR1MAOBMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | claimed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | claimed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | claimed |
| WO-2022132049-A1 | TREATING CANCERS USING BET INHIBITORS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-06-23 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-3226898-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016090219-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20150335656-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-11-26 | — | — | US | disclosed |
| US-9125915-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20130261109-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-03 | — | — | US | disclosed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | disclosed |
| CN-1097417-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | CN | disclosed |
| CN-1089947-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261109-A1 | ANTITUMOR AGENT | BRPF3, BRDT, BRD4 | TGM2 2677/4885CYP1A2 4877/4885NPSR1 3480/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | TGM2 2036/4885CYP1A2 4596/4885NPSR1 3994/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | TGM2 2036/4885CYP1A2 4596/4885NPSR1 3994/4885 |
| US-20100286127-A1 | ANTITUMOR AGENT | BRDT, HDAC1, BRPF3 | TGM2 2619/4885CYP1A2 4873/4885NPSR1 3987/4885 |
| US-20150335656-A1 | ANTITUMOR AGENT | BRPF3, BRDT, BRD4 | TGM2 2677/4885CYP1A2 4877/4885NPSR1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.